Standing up in public for a broader conception of value in healthcare.

17-24 of 72 News

viewpoint 5/15/17

On the Health Affairs Blog: Sachs Reviews Key Provisions of FDA's User Fee Reauthorization Bill Rachel Sachs provides an update of the progress of the new FDA user fee reauthorization bill and its key provisions. Sachs outlines the revisions to the law and overall goals, as well as other possible obstacles to the bill's passage in the near future. READ MORE

viewpoint 5/12/17

On the Health Affairs Blog: Hwang and Kesselheim Analyze the Impact of Taxing Drug Price Spikes Thomas Hwang and Aaron Kesselheim focus on recent efforts to establish an excise tax on drugs with significant price increases as a means of lowering drug costs and improving transparency. READ MORE

viewpoint 5/09/17

On the Health Affairs Blog: Lakdawalla and Balch Make the Case for Patient-Centered Assessment of Value IVI's Darius Lakdawalla and Alan Balch stress the need to begin actively incorporating the patient perspective into the measures used to assess value in healthcare. READ MORE

viewpoint 5/04/17

On the Health Affairs Blog: Orphan Drugs, Pursuing Value, and Avoiding Unintended Effects of Regulations Joshua Liao and Mark Pauly explain why high prices are an unintended effect of government regulation, and suggest some potential solutions. READ MORE

viewpoint 5/03/17

On the Health Affairs Blog: Bateman-House, McBride-Folkers and Caplan Examine 'Right To Try" Bill Myths and Realities Alison Bateman-House, Kelly McBride-Folkers and Arthur Caplan discuss limitations in the Trickett Wendler Right to Try Act and suggest several measures for facilitating pre-approval access to drugs. READ MORE

viewpoint 5/01/17

On the Health Affairs Blog: FDA's Scott Gottlieb and the Goldilocks Theory Ian Spatz examines the challenges facing FDA commissioner Scott Gottleib and applies the "Goldilocks Theory" to the process of senators trying to determine if the FDA is too lenient or too tough in reviewing new prescription drugs. READ MORE

viewpoint 4/27/17

On the Health Affairs Blog: Lakdawalla, Sachs, and Bagley Focus on Medicaid’s Best-Price Rule and Trump Administration Opportunity to Advance Value-Based Pricing IVI’s Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid’s best-price rule complicates the development of value-based pricing, and suggest a potential solution that could come out of new Trump administration CMS policies. READ MORE

viewpoint 4/24/17

On the Health Affairs Blog: Sood, Buckley and Strom Present a Win-Win Strategy for Improving Access to Hepatitis C Medicines Neeraj Sood, Gillian Buckley, and Brian Strom present a strategy to improve patient access to Hepatitis C medicines by having pharma patent holders license their patents to the federal government. READ MORE